Researchers at the Colorado Blood Cancer Institute have devised a successful, long-term treatment for relapsing/remitting multiple sclerosis (RRMS). The treatment approach seeks to ‘reboot’ the patient’s immune system by effectively erasing it and then rebooting it using the patient’s own [autologous] stem cells. The treatment resulted in a disease reversal rate of 86% and halted progression rate of 91% in patients participating in the study. Study patients underwent immunosuppressive therapy for up to four weeks, after which autologous stem cells were re-infused to restore a healthy immune systems. Patients were then followed for up to five years.
In a newly published phase II clinical trial from the Asan Medical Center in Seoul, Korea, researchers observed full recovery from fistulas [abnormal connections between organs caused by the inflammation] in 75% of patients suffering from Crohn’s disease upon the injection of autologous [the patient’s own] stem cells. MSCs have the ability to regulate the patient’s immune system to reduce inflammation, resulting in the complete closure of the fistulas without recurrence.
Topics: large intestine, bank dental stem cells, Crohn's Disease, autologousstemcells, autoimmune disease, gastrointestinal disease, autoimmune attack, research, StemSave, mesenchymal stem cells, organs, stem cells, Fistulas
In a recently published study, a team of researchers led by Dr. Giovanni Mancardi from the University of Genoa conducted a phase II clinical trial to compare the effectiveness of conventional multiple sclerosis [MS] therapy to intravenous stem cell transplantation. Throughout the four year trial, the team found that, in addition to significantly decreasing disease progression and brain damage compared to MS drug mitoxantrone [MTX], the transplanted stem cells had migrated into the patients’ bone marrow and stimulated the generation of new, non-harmful immune cells, essentially resetting the immune system.